Differences in maximum HbF levels attained following HU and 5-aza-CdR treatment in patients who did not increase their HbF levels after compliant HU therapy
| Patient . | Pre Rx HbF % . | Post Rx HU HbF % . | Post Rx 5-aza-CdR HbF % . |
|---|---|---|---|
| 1 | 2.3 | 1.3 | 10.7 (0.25) |
| 2 | 4.3 | 5.5 | 15.0 (0.25) |
| 3 | 0.9 | 1.1 | 13.9 (0.30) |
| 4 | 0.5 | 0.3 | 11.2 (0.30) |
| 5 | 3.4 | 4.3 | 13.1 (0.25) |
| ± SD | 2.28 ± 1.61 | 2.60 ± 2.15 | 12.70 ± 1.81* |
| Patient . | Pre Rx HbF % . | Post Rx HU HbF % . | Post Rx 5-aza-CdR HbF % . |
|---|---|---|---|
| 1 | 2.3 | 1.3 | 10.7 (0.25) |
| 2 | 4.3 | 5.5 | 15.0 (0.25) |
| 3 | 0.9 | 1.1 | 13.9 (0.30) |
| 4 | 0.5 | 0.3 | 11.2 (0.30) |
| 5 | 3.4 | 4.3 | 13.1 (0.25) |
| ± SD | 2.28 ± 1.61 | 2.60 ± 2.15 | 12.70 ± 1.81* |
Values within parentheses are doses of 5-aza-CdR (mg/kg per day).
P < .001, paired t-test.